Previous 10 | Next 10 |
2024-02-26 05:04:34 ET Alvotech ( NASDAQ: ALVO ) and partner Teva Pharmaceuticals ( NYSE: TEVA ) announced Friday the U.S. Food and Drug Administration (FDA) approval for their arthritis injection, Simlandi (adalimumab-ryvk).... Read the full article on Seeking Alp...
SIMLANDI is t he first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S . SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market...
Results demonstrate rapid and sustained suppression of free TL1A, confirming target engagement of anti-TL1A (TEV-’574) 1 Anti-TL1A (TEV-’574) was shown to be safe and well-tolerated, with a low incidence of antidrug antibodies 2 Data support the ongoing Phase...
2024-02-19 08:11:40 ET Summary Today, we revisit Corcept Therapeutics, which recently posted solid Q4 results but also faces litigation challenges. The biopharma concern is focused on developing drugs for severe metabolic, oncologic, endocrine, and neurological disorders. 2024...
2024-02-15 13:56:43 ET Summary Teva Pharmaceutical's financial performance is not strong, with high debt, lack of margin improvements, and no growth catalysts. The company's margins and profitability have been poor, with ongoing legal battles and declining revenues. Uncertaint...
2024-02-15 06:08:28 ET Summary Teva Pharmaceutical has experienced a significant downturn in the last decade but has recently shown signs of recovery. The company has stabilized its operating income of around $3 billion for the past five years, but its large debt load is holding b...
2024-02-14 18:00:17 ET Billionaire Larry Robbins' Glenview Capital Management took new positions in semiconductor firm Marvell Technology ( NASDAQ: MRVL ) and managed care player CVS Health ( CVS ) in Q4 2023, while exiting its stake in Microsoft ( NASDAQ: MSFT ) and cut...
2024-02-12 09:36:15 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript) Teva: 4 Key Drivers F...
2024-02-10 20:30:24 ET Summary Neurocrine Biosciences' shares have sold off post-earnings on concerns about its near-term opex spending and slowing growth for lead drug Ingrezza. Higher-than-expected opex spending includes targeted spending to grow the Ingrezza business (Huntingto...
2024-02-09 22:17:09 ET Summary David Abrams' 13F portfolio value increased from $3.03B to $3.22B this quarter. Meta Platforms and Teva Pharmaceutical saw stake decreases in Abrams' portfolio. Abrams kept steady positions in Lithia Motors, Asbury Automotive, Alphabet Inc., and ...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...